Cargando…

A Novel Treatment of Opioid Cravings With an Effect Size of .73 for Unilateral Transcranial Photobiomodulation Over Sham

BACKGROUND: Opioid use disorders (OUDs) are an epidemic causing catastrophic consequences to individuals, families, and society despite treatments including psychotherapy, substitution therapy or receptor blockers, and psychoeducation. We have developed a novel treatment that combines unilateral tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiffer, Fredric, Reichmann, William, Flynn, Edward, Hamblin, Michael R., McCormack, Hannah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466767/
https://www.ncbi.nlm.nih.gov/pubmed/32973577
http://dx.doi.org/10.3389/fpsyt.2020.00827
_version_ 1783577888497336320
author Schiffer, Fredric
Reichmann, William
Flynn, Edward
Hamblin, Michael R.
McCormack, Hannah
author_facet Schiffer, Fredric
Reichmann, William
Flynn, Edward
Hamblin, Michael R.
McCormack, Hannah
author_sort Schiffer, Fredric
collection PubMed
description BACKGROUND: Opioid use disorders (OUDs) are an epidemic causing catastrophic consequences to individuals, families, and society despite treatments including psychotherapy, substitution therapy or receptor blockers, and psychoeducation. We have developed a novel treatment that combines unilateral transcranial photobiomodulation (t-PBM) to the hemisphere with a more positive valence by Dual Brain Psychology (DBP). METHODS: We used a randomized, double blind, placebo-controlled protocol in which 22 patients with significant opioid cravings and a history of recent or current OUD attended three 1-h weekly sessions. After baseline measures of opioid craving and other psychometrics, subjects received two unilateral t-PBM applications (810 nm CW LED, 250 mW/cm(2), 60 J/cm(2), 4 min) or a sham (foil-covered LED) at F3 or F4. Prior to any treatment we used two tests to determine which hemisphere was more associated with a negative outlook and cravings and treated that side before the more positive hemisphere. Primary outcome measure was an opioid craving scale (OCS). Secondary outcomes were weekly Hamilton Depression (HDRS) and Anxiety (HARS) Rating Scales prior to treatments and at follow-up. RESULTS: Immediately after treatment the OCS improved significantly for both the sham and active treatments, but one week later the active treatment showed a 51.0% (SD 33.7) decrease in OCS while a week after the sham treatments there was a decrease of only 15.8% (SD 35.0) (by Wilcoxon Sign Rank Test, p = 0.004) and by a mixed model it was p = 0.0071. The effect size for the differences between active and sham was 0.73. For the active treatment from before and after treatment the effect size was 1.51 and for the sham, 0.45. The HDRS improved from a baseline of 15.1 to 8.8 (SD 10.3) a week after the active treatment and to 13.3 (SD 12.9) after the sham (p = 0.0071). HARS improved from 14.7 to 8.0 (SD 13.2) after the active treatments and to 14.3 (SD 16.0) after the sham, p = 0.08. Active treatment of the positive hemisphere after the negative hemisphere significantly improved the OCS, but there was no significant difference after the sham treatment. One patient complained of 2 h of abdominal bloating and dropped out; no other adverse effects were observed. DISCUSSION: Unilateral t-PBM to the hemisphere with a more positive hemispheric emotional valence was an effective and safe treatment for opioid cravings as well as for depression and anxiety. Our results also lend support to the underlying premises of DBP.
format Online
Article
Text
id pubmed-7466767
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74667672020-09-23 A Novel Treatment of Opioid Cravings With an Effect Size of .73 for Unilateral Transcranial Photobiomodulation Over Sham Schiffer, Fredric Reichmann, William Flynn, Edward Hamblin, Michael R. McCormack, Hannah Front Psychiatry Psychiatry BACKGROUND: Opioid use disorders (OUDs) are an epidemic causing catastrophic consequences to individuals, families, and society despite treatments including psychotherapy, substitution therapy or receptor blockers, and psychoeducation. We have developed a novel treatment that combines unilateral transcranial photobiomodulation (t-PBM) to the hemisphere with a more positive valence by Dual Brain Psychology (DBP). METHODS: We used a randomized, double blind, placebo-controlled protocol in which 22 patients with significant opioid cravings and a history of recent or current OUD attended three 1-h weekly sessions. After baseline measures of opioid craving and other psychometrics, subjects received two unilateral t-PBM applications (810 nm CW LED, 250 mW/cm(2), 60 J/cm(2), 4 min) or a sham (foil-covered LED) at F3 or F4. Prior to any treatment we used two tests to determine which hemisphere was more associated with a negative outlook and cravings and treated that side before the more positive hemisphere. Primary outcome measure was an opioid craving scale (OCS). Secondary outcomes were weekly Hamilton Depression (HDRS) and Anxiety (HARS) Rating Scales prior to treatments and at follow-up. RESULTS: Immediately after treatment the OCS improved significantly for both the sham and active treatments, but one week later the active treatment showed a 51.0% (SD 33.7) decrease in OCS while a week after the sham treatments there was a decrease of only 15.8% (SD 35.0) (by Wilcoxon Sign Rank Test, p = 0.004) and by a mixed model it was p = 0.0071. The effect size for the differences between active and sham was 0.73. For the active treatment from before and after treatment the effect size was 1.51 and for the sham, 0.45. The HDRS improved from a baseline of 15.1 to 8.8 (SD 10.3) a week after the active treatment and to 13.3 (SD 12.9) after the sham (p = 0.0071). HARS improved from 14.7 to 8.0 (SD 13.2) after the active treatments and to 14.3 (SD 16.0) after the sham, p = 0.08. Active treatment of the positive hemisphere after the negative hemisphere significantly improved the OCS, but there was no significant difference after the sham treatment. One patient complained of 2 h of abdominal bloating and dropped out; no other adverse effects were observed. DISCUSSION: Unilateral t-PBM to the hemisphere with a more positive hemispheric emotional valence was an effective and safe treatment for opioid cravings as well as for depression and anxiety. Our results also lend support to the underlying premises of DBP. Frontiers Media S.A. 2020-08-19 /pmc/articles/PMC7466767/ /pubmed/32973577 http://dx.doi.org/10.3389/fpsyt.2020.00827 Text en Copyright © 2020 Schiffer, Reichmann, Flynn, Hamblin and McCormack http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Schiffer, Fredric
Reichmann, William
Flynn, Edward
Hamblin, Michael R.
McCormack, Hannah
A Novel Treatment of Opioid Cravings With an Effect Size of .73 for Unilateral Transcranial Photobiomodulation Over Sham
title A Novel Treatment of Opioid Cravings With an Effect Size of .73 for Unilateral Transcranial Photobiomodulation Over Sham
title_full A Novel Treatment of Opioid Cravings With an Effect Size of .73 for Unilateral Transcranial Photobiomodulation Over Sham
title_fullStr A Novel Treatment of Opioid Cravings With an Effect Size of .73 for Unilateral Transcranial Photobiomodulation Over Sham
title_full_unstemmed A Novel Treatment of Opioid Cravings With an Effect Size of .73 for Unilateral Transcranial Photobiomodulation Over Sham
title_short A Novel Treatment of Opioid Cravings With an Effect Size of .73 for Unilateral Transcranial Photobiomodulation Over Sham
title_sort novel treatment of opioid cravings with an effect size of .73 for unilateral transcranial photobiomodulation over sham
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466767/
https://www.ncbi.nlm.nih.gov/pubmed/32973577
http://dx.doi.org/10.3389/fpsyt.2020.00827
work_keys_str_mv AT schifferfredric anoveltreatmentofopioidcravingswithaneffectsizeof73forunilateraltranscranialphotobiomodulationoversham
AT reichmannwilliam anoveltreatmentofopioidcravingswithaneffectsizeof73forunilateraltranscranialphotobiomodulationoversham
AT flynnedward anoveltreatmentofopioidcravingswithaneffectsizeof73forunilateraltranscranialphotobiomodulationoversham
AT hamblinmichaelr anoveltreatmentofopioidcravingswithaneffectsizeof73forunilateraltranscranialphotobiomodulationoversham
AT mccormackhannah anoveltreatmentofopioidcravingswithaneffectsizeof73forunilateraltranscranialphotobiomodulationoversham
AT schifferfredric noveltreatmentofopioidcravingswithaneffectsizeof73forunilateraltranscranialphotobiomodulationoversham
AT reichmannwilliam noveltreatmentofopioidcravingswithaneffectsizeof73forunilateraltranscranialphotobiomodulationoversham
AT flynnedward noveltreatmentofopioidcravingswithaneffectsizeof73forunilateraltranscranialphotobiomodulationoversham
AT hamblinmichaelr noveltreatmentofopioidcravingswithaneffectsizeof73forunilateraltranscranialphotobiomodulationoversham
AT mccormackhannah noveltreatmentofopioidcravingswithaneffectsizeof73forunilateraltranscranialphotobiomodulationoversham